The Fc receptor, FcRI, and other activation molecules on human mononuclear phagocytes after treatment with interferon-gamma.
Human monocytes and the myeloid cell lines U937 and HL60 have been tested with monoclonal antibodies (MoAbs) reactive with 22 different cell surface molecules before and after treatment with interferon-gamma (IFN-gamma). An increase in the expression of the high affinity Fc receptor, FcRI, and the receptor for interleukin 2, IL-2R, were the most consistent alterations which were observed. In addition, expression of the gp55 molecule recognized by CD14 MoAbs was decreased on monocytes. Of the MHC Class II molecules, there was little expression by the myeloid cell lines and no enhancement after IFN-gamma treatment. In contrast monocytes expressed all three MHC Class II subloci with DR much greater than DQ and DP. However there was much variation in IFN-gamma-mediated increase in expression of the individual subregions. In monocytes, the alteration in expression of FcRI, IL-2R, gp55 and MHC Class II molecules took place in a co-ordinate fashion and reached a plateau only after 48 h. In U937 cells, activation proceeded more rapidly and was at maximum levels between 12-16 h. This increase in FcRI appears to be a hallmark of IFN-gamma activation for mononuclear phagocytes (Mph) as the other alterations are either not found on all types of Mph (gp55, MHC Class II) or are induced by other cytokines on Mph and on other cells (IL-2R, MHC Class II). Conversely, other cytokines do not induce FcRI on Mph. These results also suggest that the cell membrane phenotypic changes induced in Mph by IFN-gamma may not be extensive and that FcRI must play a specific role in the IFN-gamma-activated Mph.
Jayaram
Y
Y
Macrophage Laboratory, Imperial Cancer Research Fund, London, UK.
Buckle
A M
AM
Hogg
N
N
D000954:Antigens, Surface / Q000032:analysis*; D002460:Cell Line; D006681:HLA-D Antigens / Q000032:analysis; D006801:Humans; D007370:Interferon Type I / Q000494:pharmacology; D007371:Interferon-gamma / Q000494:pharmacology*; D009000:Monocytes / Q000187:drug effects / Q000276:immunology; D010586:Phagocytes / Q000187:drug effects / Q000276:immunology*; D011961:Receptors, Fc / Q000032:analysis* / Q000187:drug effects; D015375:Receptors, Interleukin-2 / Q000032:analysis
D000954:Antigens, Surface; D006681:HLA-D Antigens; D007370:Interferon Type I; D011961:Receptors, Fc; D015375:Receptors, Interleukin-2; D007371:Interferon-gamma